BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/14/2022 8:30:45 AM | Browse: 236 | Download: 459
 |
Received |
|
2022-05-28 16:13 |
|
Peer-Review Started |
|
2022-05-28 16:15 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-08-01 23:01 |
|
Revised |
|
2022-08-08 11:49 |
|
Second Decision |
|
2022-09-16 03:23 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-09-16 16:50 |
|
Articles in Press |
|
2022-09-16 16:50 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-09-01 04:15 |
|
Typeset the Manuscript |
|
2022-10-08 10:14 |
|
Publish the Manuscript Online |
|
2022-10-14 08:30 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Minireviews |
| Article Title |
New therapeutic approaches for type 1 diabetes: Disease-modifying therapies
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Geza Nagy, Tekla Evelin Szekely, Aniko Somogyi, Magdolna Herold and Zoltan Herold |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Geza Nagy, MD, PhD, Assistant Professor, Department of Internal Medicine and Hematology, Semmelweis University, Szentkiralyi u. 46, Budapest H-1088, Hungary. nagy.geza@med.semmelweis-univ.hu |
| Key Words |
Type 1 diabetes; Mesenchymal stem cell; Immunotherapy; Islet cells; Autoimmunity; Regenerative medicine |
| Core Tip |
Our knowledge is rapidly growing about the pathomechanism of type 1 diabetes mellitus, and new and improved therapies have emerged. However, the long-term complications and the required lifestyle changes cannot be eliminated. There is a growing number of research that aims to find specific immunological markers/targets that have a role in disease development. The ultimate goal is finding new therapeutic ways to treat the disease and to delay or even prevent its development. The aim of this review was to provide a brief insight into the current state of disease-modifying therapeutic interventions that may impact future diabetes care. |
| Publish Date |
2022-10-14 08:30 |
| Citation |
Nagy G, Szekely TE, Somogyi A, Herold M, Herold Z. New therapeutic approaches for type 1 diabetes: Disease-modifying therapies. World J Diabetes 2022; 13(10): 835-850 |
| URL |
https://www.wjgnet.com/1948-9358/full/v13/i10/835.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v13.i10.835 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
